Ratings by Wells Fargo (Jim Birchenough)
Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
---|---|---|---|---|---|---|---|---|
1/4/2023 | Sangamo BioSciences | SGMO | Maintain | Overweight (N/A) |
|
Details | ||
11/7/2022 | Sangamo BioSciences | SGMO | Maintain | Overweight (N/A) |
|
Details | ||
8/9/2022 | uniQure BV | QURE | Maintain | Equal Weight (N/A) |
|
Details | ||
8/9/2022 | Global Blood Therapeutics | GBT | Downgrade | Equal Weight (Overweight) |
66.60 (68.49) |
2.84% | Details | |
2/9/2022 | Zymeworks | ZYME | Maintain | Overweight (N/A) |
|
Details | ||
9/30/2021 | Zymeworks | ZYME | Maintain | Overweight (N/A) |
|
Details | ||
3/18/2021 | Sangamo BioSciences | SGMO | Maintain | Overweight (N/A) |
|
Details | ||
3/3/2021 | Sangamo BioSciences | SGMO | Maintain | Overweight (N/A) |
|
Details | ||
3/2/2021 | Tracon Pharmaceuticals | TCON | Maintain | Equal Weight (N/A) |
|
Details | ||
1/12/2021 | Zymeworks | ZYME | Maintain | Overweight (N/A) |
|
Details | ||
12/7/2020 | CRISPR Therapeutics | CRSP | Downgrade | Equal Weight (Overweight) |
140.46 (52.78) |
-62.42% | Details | |
11/23/2020 | Moderna | MRNA | New Coverage | Equal Weight (N/A) |
97.61 (189.35) |
93.99% | Details | |
11/17/2020 | Applied Genetic Technologies Corp. | AGTC | Maintain | Overweight (N/A) |
|
Details | ||
11/11/2020 | Tracon Pharmaceuticals | TCON | Maintain | Equal Weight (N/A) |
|
Details | ||
11/11/2020 | Five Prime Therapeutics | FPRX | Upgrade | Overweight (Equal Weight) |
5.49 (38.00) |
592.17% | Details | |
11/10/2020 | Voyager Therapeutics | VYGR | Downgrade | Equal Weight (Overweight) |
10.98 (9.01) |
-17.94% | Details | |
10/30/2020 | Bellicum Pharmaceuticals | BLCM | Downgrade | Equal Weight (Overweight) |
6.40 (1.27) |
-80.16% | Details | |
10/29/2020 | Gilead Sciences | GILD | Maintain | Equal Weight (N/A) |
|
Details | ||
10/15/2020 | Global Blood Therapeutics | GBT | Maintain | Overweight (N/A) |
|
Details | ||
10/5/2020 | MyoKardia | MYOK | Downgrade | Equal Weight (Overweight) |
139.60 (224.91) |
61.11% | Details | |
8/31/2020 | Akcea Therapeutics, Inc. | AKCA | Downgrade | Equal Weight (Overweight) |
11.38 (18.17) |
59.67% | Details | |
8/19/2020 | Gilead Sciences | GILD | Maintain | Equal Weight (N/A) |
|
Details | ||
8/7/2020 | Principia Biopharma | PRNB | Maintain | Overweight (N/A) |
|
Details | ||
7/28/2020 | CRISPR Therapeutics | CRSP | Maintain | Overweight (N/A) |
|
Details | ||
6/25/2020 | uniQure BV | QURE | Downgrade | Equal Weight (Overweight) |
67.74 (21.24) |
-68.64% | Details | |
5/26/2020 | Regeneron Pharma | REGN | Upgrade | Overweight (Equal Weight) |
569.91 (742.83) |
30.34% | Details | |
5/18/2020 | IMV Inc. | IMV | Upgrade | Overweight (Equal Weight) |
2.30 (2.16) |
-6.09% | Details | |
4/20/2020 | Gilead Sciences | GILD | Downgrade | Equal Weight (Overweight) |
76.54 (83.73) |
9.39% | Details | |
3/19/2020 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
3/11/2020 | Sunesis Pharmaceuticals Inc. | SNSS | Downgrade | Equal Weight (Overweight) |
0.97 (5.32) |
448.45% | Details | |
2/28/2020 | IMV Inc. | IMV | Maintain | Equal Weight (N/A) |
|
Details | ||
2/25/2020 | IMV Inc. | IMV | Downgrade | Equal Weight (Overweight) |
4.78 (2.30) |
-51.88% | Details | |
2/7/2020 | Principia Biopharma | PRNB | Maintain | Overweight (N/A) |
|
Details | ||
1/21/2020 | IMV Inc. | IMV | Upgrade | Overweight (Equal Weight) |
4.00 (4.78) |
19.5% | Details | |
1/15/2020 | Zymeworks | ZYME | Maintain | Overweight (N/A) |
|
Details | ||
12/17/2019 | Intercept Pharmaceuticals | ICPT | Maintain | Overweight (N/A) |
|
Details | ||
12/9/2019 | Principia Biopharma | PRNB | Maintain | Overweight (N/A) |
|
Details | ||
12/9/2019 | Fate Therapeutics | FATE | Upgrade | Overweight (Equal Weight) |
13.57 (5.92) |
-56.37% | Details | |
11/11/2019 | Zymeworks | ZYME | Maintain | Overweight (N/A) |
|
Details | ||
11/1/2019 | Celgene | CELG | Maintain | Equal Weight (N/A) |
|
Details | ||
10/28/2019 | IMV Inc. | IMV | New Coverage | Equal Weight (N/A) |
2.96 (2.16) |
-27.03% | Details | |
10/10/2019 | Ionis Pharmaceuticals | IONS | Maintain | Overweight (N/A) |
|
Details | ||
10/7/2019 | Akcea Therapeutics, Inc. | AKCA | Upgrade | Overweight (Equal Weight) |
15.13 (11.38) |
-24.79% | Details | |
9/23/2019 | Akcea Therapeutics, Inc. | AKCA | New Coverage | Equal Weight (N/A) |
22.46 (15.13) |
-32.64% | Details | |
7/15/2019 | Gilead Sciences | GILD | Upgrade | Overweight (Equal Weight) |
66.19 (83.73) |
26.5% | Details | |
5/3/2019 | Intercept Pharmaceuticals | ICPT | Upgrade | Overweight (Equal Weight) |
85.82 (77.49) |
-9.71% | Details | |
4/22/2019 | Zymeworks | ZYME | Maintain | Overweight (N/A) |
|
Details | ||
3/7/2019 | Intercept Pharmaceuticals | ICPT | Maintain | Equal Weight (N/A) |
|
Details | ||
2/28/2019 | uniQure BV | QURE | Maintain | Overweight (N/A) |
|
Details | ||
2/7/2019 | Sangamo BioSciences | SGMO | Maintain | Overweight (N/A) |
|
Details | ||
12/21/2018 | Tracon Pharmaceuticals | TCON | Maintain | Equal Weight (N/A) |
|
Details | ||
12/6/2018 | OncoMed Pharmaceuticals | OMED | Downgrade | Equal Weight (Overweight) |
1.11 (0.89) |
-19.82% | Details | |
12/3/2018 | Tesaro | TSRO | Downgrade | Equal Weight (Overweight) |
46.38 (74.96) |
61.62% | Details | |
10/31/2018 | Intercept Pharmaceuticals | ICPT | Maintain | Equal Weight (N/A) |
|
Details | ||
10/25/2018 | Celgene | CELG | Maintain | Equal Weight (N/A) |
|
Details | ||
10/10/2018 | CRISPR Therapeutics | CRSP | New Coverage | Overweight (N/A) |
36.56 (52.78) |
44.37% | Details | |
10/9/2018 | Principia Biopharma | PRNB | New Coverage | Overweight (N/A) |
26.37 (100.05) |
279.41% | Details | |
9/24/2018 | Applied Genetic Technologies Corp. | AGTC | Upgrade | Overweight (Equal Weight) |
4.40 (0.27) |
-93.86% | Details | |
9/4/2018 | Aeglea Biotherapeutics | AGLE | Downgrade | Equal Weight (Overweight) |
10.93 (0.51) |
-95.33% | Details | |
8/28/2018 | Akcea Therapeutics, Inc. | AKCA | Maintain | Overweight (N/A) |
|
Details | ||
8/28/2018 | Ionis Pharmaceuticals | IONS | Maintain | Overweight (Overweight) |
|
Details |